Atorvastatin donor pre-treatment in a model of brain death and allogeneic kidney transplantation in rats

Annals of Transplantation

Volumn 17, Issue 1, 2012, Pages 79-85

  Hoeger, Simone ^a   Benck, Urs ^a   Petrov, Kiril ^a   Waldherr, Rüdiger ^b   Schnuelle, Peter ^a   Yard, Benito A ^a   Krämer, Bernhard K ^a   Gottmann, Uwe ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

Atorvastatin; Brain death; Cold preservation; Donor pre treatment; Kidney transplantation; Rat

Indexed keywords

ATORVASTATIN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEATH; CELL INFILTRATION; CONTROLLED STUDY; DONOR; DRUG EFFECT; HISTOLOGY; KIDNEY PRESERVATION; KIDNEY TRANSPLANTATION; MALE; NEPHRITIS; NONHUMAN; RAT; VASCULAR DISEASE;

EID: 84859376771     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.882639     Document Type: Article

References (38)

1. Suthanthiran M, Strom TB: Renal transplantation. N Engl J Med, 1994; 331: 365-76.
2. Eurotransplant. Annual Report 2010. 2011
3. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S: High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med, 1995; 333: 333-36.
4. Pratschke J, Wilhelm MJ, Kusaka M et al: Acute rejection of rat renal allografts is accelerated by donor brain death. Transplant Proc, 1999; 31: 874-75.
5. Goes N, Urmson J, Ramassar V, Halloran PF: Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colonystimulating factor, interleukin-2, and interleukin-10. Transplantation, 1995; 59: 565-72.
6. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol, 1994; 12: 991-1045.
7. van der Woude FJ: Graft immunogenicity revisited: relevance of tissue-specific immunity, brain death and donor pretreatment. Nephron, 2002; 91: 181-87.
8. Caban A, Budzinski G, Oczkowicz G et al: Factors determining changes in concentrations of pro-inflammatory markers in blood serum in the initial period after kidney transplantation from dead donor. Ann Transplant, 2009; 14: 10-13.
9. Kloda K, Domanski L, Pawlik A, Kurzawski M et al: Effect of the ICAM1 and VCAM1 gene polymorphisms on delayed graft function and acute kidney allograft rejection. Ann Transplant, 2010; 15: 15-20.
10. Gjertson DW: Impact of delayed graft function and acute rejection on kidney graft survival. Clin Transpl, 2000: 467-80.
11. Hoeger S, Reisenbuechler A, Gottmann U et al: Donor dopamine treatment in brain dead rats is associated with an improvement in renal function early after transplantation and a reduction in renal inflammation. Transpl Int, 2008; 21: 1072-80.
12. de Vries DK, Lindeman JH, Ringers J et al: Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant, 2011; 11: 1064-70.
13. Hoeger S, Gottmann U, Liu Z et al: Dopamine treatment in brain-dead rats mediates anti-inflammatory effects: the role of hemodynamic stabilization and D-receptor stimulation. Transpl Int, 2007; 20: 790-99.
14. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ: Kidney grafts from brain dead donors: Inferior quality or opportunity for improvement? Kidney Int, 2007; 72: 797-805.
15. Pratschke J, Tullius SG, Neuhaus P: Brain death associated ischemia/reperfusion injury. Ann Transplant, 2004; 9: 78-80.
16. Hoeger S, Petrov K, Reisenbuechler A et al: The additional detrimental effects of cold preservation on transplantation-associated injury in kidneys from living and brain-dead donor rats. Transplantation, 2009; 87: 52-58.
17. Pratschke J, Wilhelm MJ, Kusaka M et al: Accelerated rejection of renal allografts from braindead donors. Ann Surg, 2000; 232: 263-71.
18. Pratschke J, Wilhelm MJ, Laskowski I et al: Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol, 2001; 12: 2474-81.
19. Pratschke J, Kofla G, Wilhelm MJ et al: Improvements in early behavior of rat kidney allografts after treatment of the brain-dead donor. Ann Surg, 2001; 234: 732-40.
20. Schaub M, Ploetz CJ, Gerbaulet D et al: Effect of dopamine on inflammatory status in kidneys of brain-dead rats. Transplantation, 2004; 77: 1333-40.
21. Schnuelle P, Gottmann U, Hoeger S et al: Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA, 2009; 302: 1067-75.
22. Hoeger S, Bergstraesser C, Selhorst J et al: Modulation of brain dead induced inflammation by vagus nerve stimulation. Am J Transplant, 2010; 10: 477-89.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-89.
24. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349-57.
25. Mach F: Statins as immunomodulatory agents. Circulation, 2004; 109: II15-II17.
26. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med, 2000; 6: 1399-402.
27. Katznelson S, Wilkinson AH, Kobashigawa JA et al: The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation, 1996; 61: 1469-74.
28. Ji P, Si MS, Podnos Y et al: Prevention of chronic rejection by pravastatin in a rat kidney transplant model. Transplantation, 2002; 74: 821-27.
29. Holdaas H, Fellstrom B, Jardine AG et al: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet, 2003; 361: 2024-31.
30. Fellstrom B, Holdaas H, Jardine AG et al: Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int, 2004; 66: 1549-55.
31. Gueler F, Rong S, Park JK et al: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol, 2002; 13: 2288-98.
32. Joyce M, Kelly C, Winter D et al: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res, 2001; 101: 79-84.
33. Yokota N, O'Donnell M, Daniels F et al: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol, 2003; 23: 13-17.
34. Sabbatini M, Pisani A, Uccello F et al: Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol, 2004; 15: 901-9.
35. Gottmann U, Brinkkoetter PT, Hoeger S et al: Atorvastatin donor pretreatment prevents ischemia/ reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition. Transplantation, 2007; 84: 755-62.
36. Weiss S, Kotsch K, Francuski M et al: Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant, 2007; 7: 1584-93.
37. Kaminska D, Tyran B, Mazanowska O et al: Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation, 2007; 84: 1118-24.
38. Pratschke J, Wilhelm MJ, Kusaka M et al: Activation of proinflammatory genes in somatic organs as a consequence of brain death. Transplant Proc, 1999; 31: 1003-5